Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development

  • Description
  • Details
  • Subprojects
  • History
  • Relations
  • Publications
Project Title: Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development
Project Number: CORDIS-203681
Project web address: Follow on CORDIS
Organization: Glaxosmithkline Research And Development Limited, United Kingdom, Stevenage
Collaborators: University Of Bristol, GB
University Of Exeter, GB
Centre National De La Recherche Scientifique (Cnrs), FR
Università Cattolica Del Sacro Cuore, IT
Università Degli Studi Di Genova, IT
Institut National De La Sante Et De La Recherche Medicale, FR
Universita Degli Studi Di Perugia, IT
Universidad De Murcia, ES
Janssen Pharmaceutica N.V., BE
Istituto Di Ricerche Farmacologiche Mario Negri, IT
Universitaet Leipzig, DE
F. Hoffmann - La Roche Ltd., CH
H. Lundbeck A/S, DK
Eli Lilly Company Limited, GB
Merck Kommanditgesellschaft Auf Aktien, DE
Novartis Pharma Ag, CH
Astra Zeneca Ab, SE
Alzheimer Europe, LU
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, ES
Provincia Lombardo Veneta Ordine Ospedaliero Di San Giovanni Di Dio - Fatebenefratelli, IT
Universite D'Aix Marseille, FR
Universitaetsklinikum Essen, DE
Università Degli Studi Di Foggia (University Of Foggia), IT
Ucb Biopharma Sprl, BE
Universite De Lille Ii - Droit Et Sante, FR
Arc-Net Applied Research On Cancer Centre, University Of Verona, IT
Institut De Recherches Servier S.A.S, FR
Boehriger Ingelheim International Gmbh, DE
Stichting Vu, NL
Innovative Concepts In Drug Development (Icdd-Sas), FR
Diaxonhit Sa, FR
Qualissima, FR
Eisai Limited,
Sas Alzprotect, FR
Irccs Fondazione Sdn Per La Ricerca E L'Alta Formazione In Diagnostica Nucleare, IT
Innovative Health Diagnostics, FR
Greek Association Of Alzheimer'S Disease And Related Disoders, GR
Principal Investigators (PI): Jean Georges, LU
María Sánchez-Merenciano Juárez, ES
Celine Damon, FR
Pastora Martinez Samper, ES
Filippo Leone, IT
Laura Miano, IT
Eva Lindgren, SE
Simon Dresse, BE
Rolf Göggel, DE
Ninog Péresse, DE
Fra Marco Fabello, IT
Jill Richardson, GB
Slvio Garattinl, IT
Gaynor Hughes, GB
Armelle Barelli, FR
Marie Gompel, FR
Danielle Bonink, NL
Laetitia Cruien, FR
Veronique Audouard, FR
Séverine Pitel, FR
Ursula Knauf, CH
Lee Dawson,
Henk Sipma, BE
Philippe Verwaerde, FR
Esther Schenker, FR
Julie Zitel, FR
Laura Recalina, IT
David Yates, GB
Tilman Hensch, DE
Xavier Regnaut, FR
Luca Santarelli, CH
Ejner Moltzen, DK
Evi Siahoudi, GR
Sarah Everett-Cox, GB
Lucia Farotti, IT
Willibald Kroening, DE
Giovanni Lovallo, IT
Manuela Calderara, IT
 
Project Description:
PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies on a 'multidimensional matrix' approach, integrating all available and renewed inputs (biomarkers/animal, human models/physiological and pharmcological challenges, Phase 0/1/1b to reduce the attrition rate, to allow an early and pertinent GO/NOGO decision before entering phase II trials for both symptomatic treatment and disease modifiers approaches. The hypothesis is that effective long term drugs will normalize markers artificially modified. The general objective is to test the efficiency of the 'matrix' on drug candidates for the enhancement/protection of cognitive functions. the final objective is to improve the detection and selection of new drugs candidates within a shorter teim-frame.Our consortium gathers 13 academics and clinicians, 8 SMEs, 1 European patient organization (Alzheimer Europe) as well as 1 regulatory body (EMEA), coming form six different EU Members States. Excellence Centres gather representatives of the different sectors: biomarkers (proteomics, transcriptomics), pharmacodynamic markers ( electrophysiology, psychophysiology, morphological and functional imaging), preclinical model specialists (cellular, transgenic mouse, monkey), clinicians, and clinical pharmacologists.By the end of this (-year project, the following achievements are expected; definition of the most predictive combination of pharmacodynamic markers; validation of parallel models (in healthy volunteers, ApoE 4 subjects,patients and animals) to establish effective exposure ranges and support proof of mechanism studies. The predictive value of the 'matrix' will be evaluated using different pharmacological target acting drugs. Suugestions for revised/new recomendations and guidellines will help to standardize the pre-clinical and clinical phases of drugs' development in neurodegenerative diseases.
 
Project Terms:
There are no related terms in database.
Project Title: Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development
Project Number: CORDIS-203681
Project web address: Follow on CORDIS
Organization: Glaxosmithkline Research And Development Limited, United Kingdom, Stevenage
Collaborators: University Of Bristol, GB
University Of Exeter, GB
Centre National De La Recherche Scientifique (Cnrs), FR
Università Cattolica Del Sacro Cuore, IT
Università Degli Studi Di Genova, IT
Institut National De La Sante Et De La Recherche Medicale, FR
Universita Degli Studi Di Perugia, IT
Universidad De Murcia, ES
Janssen Pharmaceutica N.V., BE
Istituto Di Ricerche Farmacologiche Mario Negri, IT
Universitaet Leipzig, DE
F. Hoffmann - La Roche Ltd., CH
H. Lundbeck A/S, DK
Eli Lilly Company Limited, GB
Merck Kommanditgesellschaft Auf Aktien, DE
Novartis Pharma Ag, CH
Astra Zeneca Ab, SE
Alzheimer Europe, LU
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, ES
Provincia Lombardo Veneta Ordine Ospedaliero Di San Giovanni Di Dio - Fatebenefratelli, IT
Universite D'Aix Marseille, FR
Universitaetsklinikum Essen, DE
Università Degli Studi Di Foggia (University Of Foggia), IT
Ucb Biopharma Sprl, BE
Universite De Lille Ii - Droit Et Sante, FR
Arc-Net Applied Research On Cancer Centre, University Of Verona, IT
Institut De Recherches Servier S.A.S, FR
Boehriger Ingelheim International Gmbh, DE
Stichting Vu, NL
Innovative Concepts In Drug Development (Icdd-Sas), FR
Diaxonhit Sa, FR
Qualissima, FR
Eisai Limited,
Sas Alzprotect, FR
Irccs Fondazione Sdn Per La Ricerca E L'Alta Formazione In Diagnostica Nucleare, IT
Innovative Health Diagnostics, FR
Greek Association Of Alzheimer'S Disease And Related Disoders, GR
Principal Investigators (PI): Jean Georges, LU
María Sánchez-Merenciano Juárez, ES
Celine Damon, FR
Pastora Martinez Samper, ES
Filippo Leone, IT
Laura Miano, IT
Eva Lindgren, SE
Simon Dresse, BE
Rolf Göggel, DE
Ninog Péresse, DE
Fra Marco Fabello, IT
Jill Richardson, GB
Slvio Garattinl, IT
Gaynor Hughes, GB
Armelle Barelli, FR
Marie Gompel, FR
Danielle Bonink, NL
Laetitia Cruien, FR
Veronique Audouard, FR
Séverine Pitel, FR
Ursula Knauf, CH
Lee Dawson,
Henk Sipma, BE
Philippe Verwaerde, FR
Esther Schenker, FR
Julie Zitel, FR
Laura Recalina, IT
David Yates, GB
Tilman Hensch, DE
Xavier Regnaut, FR
Luca Santarelli, CH
Ejner Moltzen, DK
Evi Siahoudi, GR
Sarah Everett-Cox, GB
Lucia Farotti, IT
Willibald Kroening, DE
Giovanni Lovallo, IT
Manuela Calderara, IT
 
Project Categories:
Natural Sciences
 
Other Information:
Fiscal Year: 2010
Project Start Date: 1 January 2009
Project End Date: 31 December 2015
Project program: FP7-JTI
 
Project Funding Information:
Funding Mechanism: JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)
Year Funding Organization Total Funding, $
2010 European Research Council $33,549,512
Project Title: Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development
Project Number: CORDIS-203681
Project web address: Follow on CORDIS
Organization: Glaxosmithkline Research And Development Limited, United Kingdom, Stevenage
Collaborators: University Of Bristol, GB
University Of Exeter, GB
Centre National De La Recherche Scientifique (Cnrs), FR
Università Cattolica Del Sacro Cuore, IT
Università Degli Studi Di Genova, IT
Institut National De La Sante Et De La Recherche Medicale, FR
Universita Degli Studi Di Perugia, IT
Universidad De Murcia, ES
Janssen Pharmaceutica N.V., BE
Istituto Di Ricerche Farmacologiche Mario Negri, IT
Universitaet Leipzig, DE
F. Hoffmann - La Roche Ltd., CH
H. Lundbeck A/S, DK
Eli Lilly Company Limited, GB
Merck Kommanditgesellschaft Auf Aktien, DE
Novartis Pharma Ag, CH
Astra Zeneca Ab, SE
Alzheimer Europe, LU
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, ES
Provincia Lombardo Veneta Ordine Ospedaliero Di San Giovanni Di Dio - Fatebenefratelli, IT
Universite D'Aix Marseille, FR
Universitaetsklinikum Essen, DE
Università Degli Studi Di Foggia (University Of Foggia), IT
Ucb Biopharma Sprl, BE
Universite De Lille Ii - Droit Et Sante, FR
Arc-Net Applied Research On Cancer Centre, University Of Verona, IT
Institut De Recherches Servier S.A.S, FR
Boehriger Ingelheim International Gmbh, DE
Stichting Vu, NL
Innovative Concepts In Drug Development (Icdd-Sas), FR
Diaxonhit Sa, FR
Qualissima, FR
Eisai Limited,
Sas Alzprotect, FR
Irccs Fondazione Sdn Per La Ricerca E L'Alta Formazione In Diagnostica Nucleare, IT
Innovative Health Diagnostics, FR
Greek Association Of Alzheimer'S Disease And Related Disoders, GR
Principal Investigators (PI): Jean Georges, LU
María Sánchez-Merenciano Juárez, ES
Celine Damon, FR
Pastora Martinez Samper, ES
Filippo Leone, IT
Laura Miano, IT
Eva Lindgren, SE
Simon Dresse, BE
Rolf Göggel, DE
Ninog Péresse, DE
Fra Marco Fabello, IT
Jill Richardson, GB
Slvio Garattinl, IT
Gaynor Hughes, GB
Armelle Barelli, FR
Marie Gompel, FR
Danielle Bonink, NL
Laetitia Cruien, FR
Veronique Audouard, FR
Séverine Pitel, FR
Ursula Knauf, CH
Lee Dawson,
Henk Sipma, BE
Philippe Verwaerde, FR
Esther Schenker, FR
Julie Zitel, FR
Laura Recalina, IT
David Yates, GB
Tilman Hensch, DE
Xavier Regnaut, FR
Luca Santarelli, CH
Ejner Moltzen, DK
Evi Siahoudi, GR
Sarah Everett-Cox, GB
Lucia Farotti, IT
Willibald Kroening, DE
Giovanni Lovallo, IT
Manuela Calderara, IT
 
Title FY Funding
There are no results for this project in database.
Project Title: Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development
Project Number: CORDIS-203681
Project web address: Follow on CORDIS
Organization: Glaxosmithkline Research And Development Limited, United Kingdom, Stevenage
Collaborators: University Of Bristol, GB
University Of Exeter, GB
Centre National De La Recherche Scientifique (Cnrs), FR
Università Cattolica Del Sacro Cuore, IT
Università Degli Studi Di Genova, IT
Institut National De La Sante Et De La Recherche Medicale, FR
Universita Degli Studi Di Perugia, IT
Universidad De Murcia, ES
Janssen Pharmaceutica N.V., BE
Istituto Di Ricerche Farmacologiche Mario Negri, IT
Universitaet Leipzig, DE
F. Hoffmann - La Roche Ltd., CH
H. Lundbeck A/S, DK
Eli Lilly Company Limited, GB
Merck Kommanditgesellschaft Auf Aktien, DE
Novartis Pharma Ag, CH
Astra Zeneca Ab, SE
Alzheimer Europe, LU
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, ES
Provincia Lombardo Veneta Ordine Ospedaliero Di San Giovanni Di Dio - Fatebenefratelli, IT
Universite D'Aix Marseille, FR
Universitaetsklinikum Essen, DE
Università Degli Studi Di Foggia (University Of Foggia), IT
Ucb Biopharma Sprl, BE
Universite De Lille Ii - Droit Et Sante, FR
Arc-Net Applied Research On Cancer Centre, University Of Verona, IT
Institut De Recherches Servier S.A.S, FR
Boehriger Ingelheim International Gmbh, DE
Stichting Vu, NL
Innovative Concepts In Drug Development (Icdd-Sas), FR
Diaxonhit Sa, FR
Qualissima, FR
Eisai Limited,
Sas Alzprotect, FR
Irccs Fondazione Sdn Per La Ricerca E L'Alta Formazione In Diagnostica Nucleare, IT
Innovative Health Diagnostics, FR
Greek Association Of Alzheimer'S Disease And Related Disoders, GR
Principal Investigators (PI): Jean Georges, LU
María Sánchez-Merenciano Juárez, ES
Celine Damon, FR
Pastora Martinez Samper, ES
Filippo Leone, IT
Laura Miano, IT
Eva Lindgren, SE
Simon Dresse, BE
Rolf Göggel, DE
Ninog Péresse, DE
Fra Marco Fabello, IT
Jill Richardson, GB
Slvio Garattinl, IT
Gaynor Hughes, GB
Armelle Barelli, FR
Marie Gompel, FR
Danielle Bonink, NL
Laetitia Cruien, FR
Veronique Audouard, FR
Séverine Pitel, FR
Ursula Knauf, CH
Lee Dawson,
Henk Sipma, BE
Philippe Verwaerde, FR
Esther Schenker, FR
Julie Zitel, FR
Laura Recalina, IT
David Yates, GB
Tilman Hensch, DE
Xavier Regnaut, FR
Luca Santarelli, CH
Ejner Moltzen, DK
Evi Siahoudi, GR
Sarah Everett-Cox, GB
Lucia Farotti, IT
Willibald Kroening, DE
Giovanni Lovallo, IT
Manuela Calderara, IT
 
Project Title Organization FY Funding
Prediction Of Cognitive Properties Of New Drug Candidates For Neurodegenerative Diseases In The Early Clinical DevelopmentGlaxosmithkline Research And Development Limited2010$33,549,512
Project Title: Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development
Project Number: CORDIS-203681
Project web address: Follow on CORDIS
Organization: Glaxosmithkline Research And Development Limited, United Kingdom, Stevenage
Collaborators: University Of Bristol, GB
University Of Exeter, GB
Centre National De La Recherche Scientifique (Cnrs), FR
Università Cattolica Del Sacro Cuore, IT
Università Degli Studi Di Genova, IT
Institut National De La Sante Et De La Recherche Medicale, FR
Universita Degli Studi Di Perugia, IT
Universidad De Murcia, ES
Janssen Pharmaceutica N.V., BE
Istituto Di Ricerche Farmacologiche Mario Negri, IT
Universitaet Leipzig, DE
F. Hoffmann - La Roche Ltd., CH
H. Lundbeck A/S, DK
Eli Lilly Company Limited, GB
Merck Kommanditgesellschaft Auf Aktien, DE
Novartis Pharma Ag, CH
Astra Zeneca Ab, SE
Alzheimer Europe, LU
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, ES
Provincia Lombardo Veneta Ordine Ospedaliero Di San Giovanni Di Dio - Fatebenefratelli, IT
Universite D'Aix Marseille, FR
Universitaetsklinikum Essen, DE
Università Degli Studi Di Foggia (University Of Foggia), IT
Ucb Biopharma Sprl, BE
Universite De Lille Ii - Droit Et Sante, FR
Arc-Net Applied Research On Cancer Centre, University Of Verona, IT
Institut De Recherches Servier S.A.S, FR
Boehriger Ingelheim International Gmbh, DE
Stichting Vu, NL
Innovative Concepts In Drug Development (Icdd-Sas), FR
Diaxonhit Sa, FR
Qualissima, FR
Eisai Limited,
Sas Alzprotect, FR
Irccs Fondazione Sdn Per La Ricerca E L'Alta Formazione In Diagnostica Nucleare, IT
Innovative Health Diagnostics, FR
Greek Association Of Alzheimer'S Disease And Related Disoders, GR
Principal Investigators (PI): Jean Georges, LU
María Sánchez-Merenciano Juárez, ES
Celine Damon, FR
Pastora Martinez Samper, ES
Filippo Leone, IT
Laura Miano, IT
Eva Lindgren, SE
Simon Dresse, BE
Rolf Göggel, DE
Ninog Péresse, DE
Fra Marco Fabello, IT
Jill Richardson, GB
Slvio Garattinl, IT
Gaynor Hughes, GB
Armelle Barelli, FR
Marie Gompel, FR
Danielle Bonink, NL
Laetitia Cruien, FR
Veronique Audouard, FR
Séverine Pitel, FR
Ursula Knauf, CH
Lee Dawson,
Henk Sipma, BE
Philippe Verwaerde, FR
Esther Schenker, FR
Julie Zitel, FR
Laura Recalina, IT
David Yates, GB
Tilman Hensch, DE
Xavier Regnaut, FR
Luca Santarelli, CH
Ejner Moltzen, DK
Evi Siahoudi, GR
Sarah Everett-Cox, GB
Lucia Farotti, IT
Willibald Kroening, DE
Giovanni Lovallo, IT
Manuela Calderara, IT
 
Project number Project title Principal investigator
There are no any related projects.
Project Title: Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development
Project Number: CORDIS-203681
Project web address: Follow on CORDIS
Organization: Glaxosmithkline Research And Development Limited, United Kingdom, Stevenage
Collaborators: University Of Bristol, GB
University Of Exeter, GB
Centre National De La Recherche Scientifique (Cnrs), FR
Università Cattolica Del Sacro Cuore, IT
Università Degli Studi Di Genova, IT
Institut National De La Sante Et De La Recherche Medicale, FR
Universita Degli Studi Di Perugia, IT
Universidad De Murcia, ES
Janssen Pharmaceutica N.V., BE
Istituto Di Ricerche Farmacologiche Mario Negri, IT
Universitaet Leipzig, DE
F. Hoffmann - La Roche Ltd., CH
H. Lundbeck A/S, DK
Eli Lilly Company Limited, GB
Merck Kommanditgesellschaft Auf Aktien, DE
Novartis Pharma Ag, CH
Astra Zeneca Ab, SE
Alzheimer Europe, LU
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, ES
Provincia Lombardo Veneta Ordine Ospedaliero Di San Giovanni Di Dio - Fatebenefratelli, IT
Universite D'Aix Marseille, FR
Universitaetsklinikum Essen, DE
Università Degli Studi Di Foggia (University Of Foggia), IT
Ucb Biopharma Sprl, BE
Universite De Lille Ii - Droit Et Sante, FR
Arc-Net Applied Research On Cancer Centre, University Of Verona, IT
Institut De Recherches Servier S.A.S, FR
Boehriger Ingelheim International Gmbh, DE
Stichting Vu, NL
Innovative Concepts In Drug Development (Icdd-Sas), FR
Diaxonhit Sa, FR
Qualissima, FR
Eisai Limited,
Sas Alzprotect, FR
Irccs Fondazione Sdn Per La Ricerca E L'Alta Formazione In Diagnostica Nucleare, IT
Innovative Health Diagnostics, FR
Greek Association Of Alzheimer'S Disease And Related Disoders, GR
Principal Investigators (PI): Jean Georges, LU
María Sánchez-Merenciano Juárez, ES
Celine Damon, FR
Pastora Martinez Samper, ES
Filippo Leone, IT
Laura Miano, IT
Eva Lindgren, SE
Simon Dresse, BE
Rolf Göggel, DE
Ninog Péresse, DE
Fra Marco Fabello, IT
Jill Richardson, GB
Slvio Garattinl, IT
Gaynor Hughes, GB
Armelle Barelli, FR
Marie Gompel, FR
Danielle Bonink, NL
Laetitia Cruien, FR
Veronique Audouard, FR
Séverine Pitel, FR
Ursula Knauf, CH
Lee Dawson,
Henk Sipma, BE
Philippe Verwaerde, FR
Esther Schenker, FR
Julie Zitel, FR
Laura Recalina, IT
David Yates, GB
Tilman Hensch, DE
Xavier Regnaut, FR
Luca Santarelli, CH
Ejner Moltzen, DK
Evi Siahoudi, GR
Sarah Everett-Cox, GB
Lucia Farotti, IT
Willibald Kroening, DE
Giovanni Lovallo, IT
Manuela Calderara, IT
 
Title Journal Year Country Rel